Y mAbs Therapeutics Market Cap ($391.22 Million)
Market Cap & Net Worth: Y mAbs Therapeutics (YMAB)
Y mAbs Therapeutics market cap. Y mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $391.22 Million ($391.22 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13201 globally and #3234 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Y mAbs Therapeutics's stock price $8.61 by its total outstanding shares 45438400 (45.44 Million). Also see how efficiently does Y mAbs Therapeutics generate cash for how efficiently the company converts equity into cash flow.
Y mAbs Therapeutics Market Cap History (2018–2025)
Y mAbs Therapeutics market cap history from 2018 to 2025. Data shows change from $924.22 Million to $391.22 Million (-13.64% CAGR). Check YMAB stock price for real-time trading data and today's change.
Index Memberships
Y mAbs Therapeutics is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.02% | #357 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1298 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.02% | #196 of 263 |
Weight: Y mAbs Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Y mAbs Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Y mAbs Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore YMAB net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.06x
Y mAbs Therapeutics's market cap is 4.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.25 Billion | $20.75 Million | -$119.34 Million | 108.42x | N/A |
| 2021 | $736.56 Million | $34.90 Million | -$56.34 Million | 21.11x | N/A |
| 2022 | $221.74 Million | $65.27 Million | -$96.33 Million | 3.40x | N/A |
| 2023 | $309.89 Million | $84.82 Million | -$21.43 Million | 3.65x | N/A |
| 2024 | $355.78 Million | $87.69 Million | -$29.67 Million | 4.06x | N/A |
Competitor Companies of YMAB by Market Capitalization
Companies near Y mAbs Therapeutics in the global market cap rankings as of November 3, 2026. Also see Y mAbs Therapeutics balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Y mAbs Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Y mAbs Therapeutics (2018–2025)
Market capitalization of Y mAbs Therapeutics from 2018 to today. Between 2018 and today, Y mAbs Therapeutics's market cap moved from $924.22 Million to $ 391.22 Million, with a yearly change of -13.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $391.22 Million | +9.96% |
| 2024 | $355.78 Million | +14.81% |
| 2023 | $309.89 Million | +39.75% |
| 2022 | $221.74 Million | -69.90% |
| 2021 | $736.56 Million | -67.26% |
| 2020 | $2.25 Billion | +58.43% |
| 2019 | $1.42 Billion | +53.64% |
| 2018 | $924.22 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 14th, 2026 the market cap of Y mAbs Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $391.22 Million USD |
| MoneyControl | $391.22 Million USD |
| MarketWatch | $391.22 Million USD |
| marketcap.company | $391.22 Million USD |
| Reuters | $391.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more